Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) — The “Lung Cancer Diagnostics Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts” report has been added to ResearchAndMarkets.com’s offering.
The Lung Cancer Diagnostics Market is expected to witness significant growth, reaching US$ 38.00 billion by 2033 from US$ 21.74 billion in 2025, at a CAGR of 7.23% during the forecast period of 2025 to 2033.
Some of the major factors responsible for the market growth include an increasing number of public access facilities, a rise in ambulance services, and an increasing prevalence of cardiac disorders such as coronary artery diseases and arrhythmias.
Lung cancer diagnosis refers to the various techniques and technologies that may be employed for the detection and assessment of lung cancer in humans. This may involve chest X-rays, computed tomography scans, MRI, biopsies, and blood analyses. The objectives are the accurate identification of cancer at its earliest moment-that is most conducive to effective therapy and better outcomes.
Lung cancer diagnostic tests are popular worldwide since the prevalence of the disease has risen in both smokers and environmental pollutant-exposed populations. Due to increasing awareness of risks, people are turning up for early screening and diagnostic services. Medical technology is also improving day by day, creating better imaging and detection techniques that improve survival rates.
Moreover, public health campaigns for awareness about lung cancer have contributed to increased demand for diagnostics. Therefore, health systems worldwide are focusing on the need for early detection, and diagnostics of lung cancer have now become an integral part of strategies for the care and management of the disease in different populations.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2025 – 2033 |
| Estimated Market Value (USD) in 2025 | $21.74 Billion |
| Forecasted Market Value (USD) by 2033 | $38 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
Key Topics Covered:
1. Lung Cancer Diagnostics Market
1.1 Historical Trends
1.2 Forecast Analysis
2. Market Share Analysis – Lung Cancer Diagnostics Market
3. Llumina
3.1 Overview
3.1.1 Company History and Mission
3.1.2 Business Model and Operations
3.1.3 Workforce
3.2 Key Persons
3.2.1 Executive Leadership
3.2.2 Operational Management
3.2.3 Division Leaders
3.2.4 Board Composition
3.3 Recent Development & Strategies
3.3.1 Mergers & Acquisitions
3.3.2 Partnerships
3.3.3 Investments
3.4 Sustainability Analysis
3.4.1 Renewable Energy Adoption
3.4.2 Energy-Efficient Infrastructure
3.4.3 Use of Sustainable Packaging Materials
3.4.4 Water Usage and Conservation Strategies
3.4.5 Waste Management and Circular Economy Initiatives
3.5 Product Analysis
3.5.1 Product Profile
3.5.2 Quality Standards
3.5.3 Product Pipeline
3.5.4 Product Benchmarking
3.6 Strategic Assessment: SWOT Analysis
3.6.1 Strengths
3.6.2 Weaknesses
3.6.3 Opportunities
3.6.4 Threats
3.7 Revenue Analysis
Above Information Will Be Available for All the Following Companies
- llumina, Inc.
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Holding AG.
- Sanofi S.A.
- Agilent Technologies
- bioMerieux.
- Myriad Genetics, Inc.
- Siemens Healthineers AG
- Danaher Corporation
- Guardant Health, Inc.
- Veracyte, Inc.
- Natera, Inc.
- GE HealthCare
- MedGenome
- NanoString Technologies, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/k2opsn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Lung Cancer Diagnostics Market
